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Abstract 
Background 
For patients with heart failure, there is an inverse relation between body mass index (BMI) 
and mortality, sometimes called the obesity-paradox. However, the relationship might be 
either U- or J-shaped and might differ between patients with reduced (HFrEF) or preserved 
left ventricular ejection fraction (HFpEF). We sought to investigate this further in a dose-
response meta-analysis of published studies. 
Methods 
PubMed and Embase from June 1980 to April 2017 were searched for prospective cohort 
studies evaluating associations between BMI and all-cause mortality in patients with HFrEF 
(LVEF <40%) or HFpEF (LVEF ≥ 50%). Summary estimated effect sizes were obtained by 
using a random effects model. Potential non-linear relationships were evaluated by using 
random effects restricted cubic spline models.  
Results 
Ten studies were identified that included 96,424 patients of whom 59,263 had HFpEF (mean 
age 68 years of whom 38% were women) and 37,161 had HFrEF (mean age 60 years of 
whom 17% were women). For patients with HFpEF, the summary hazard ratio (HR) for all-
cause mortality was: 0.93 (95%CI: 0.89-0.97) per 5 units increase in BMI (I-squared = 
75.8%, p for heterogeneity = 0.01 and Begg’s test, p = 1.0, Egger’s test, p = 0.29) but the 
association was U-shaped (p for nonlinearity <0.01) with the nadir of risk at a BMI of 32-33 
kg/m². For patients with HFrEF, the summary HR for all-cause mortality was: 0.96 (95%CI: 
0.92-0.99) (I-squared=95%, p for heterogeneity < 0.001 and Begg’s test, p=0.45, Egger’s test, 
p=0.01). The relationship was also U-shaped (p < 0.01), although ‘flatter’ than for HFpEF, 
with the nadir at a BMI of 33 kg/m².   
Conclusions 
For patients with heart failure, the relation between BMI and mortality is U-shaped with a 
similar nadir of risk for HFpEF and HFrEF at a BMI of 32-33 kg/m². Whether interventions 
that alter weight in either direction can alter risk is unknown.  
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Introduction 
Many studies have shown that mild-to-moderate obesity is associated with a lower mortality 
amongst patients with heart failure: the so-called obesity-paradox. 1-5 The possible causes of 
the paradox are controversial. There is no doubt that BMI declines as heart failure (HF) 
becomes more severe: some believe that a low BMI simply reflects more advanced disease. 
Adherents of this view suggest that interventions to reduce a high BMI will benefit patients 
symptomatically and perhaps prognostically, by reducing pro-inflammatory visceral adiposity 
and perhaps haemodynamic stress as well as improving glycaemic control.6 Others believe 
that a higher BMI may provide a metabolic reserve as disease progresses or even be 
intrinsically beneficial, in which case efforts should be made to increase rather than reduce 
BMI. Indeed, one of the great successes of heart failure therapy, beta-blockers, increases 
BMI.7  
 
A recent study from the MAGGIC8, 9 collaboration, based on individual patient data, reported 
that there was a U-shaped relationship between BMI and all-cause mortality both for patients 
with HFpEF and those with HFrEF with the nadir of risk at a BMI of 30-34.9 kg/m². In order 
to investigate this observation further, we conducted a systematic review and dose-response 
meta-analysis to quantify and better understand the potential non-linear relation between BMI 
and prognosis in prospective cohort studies of patients with HFpEF and HFrEF. 
 
Methods 
Search Strategy  
The study was designed according to the Meta-analysis of Observational Studies in 
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Epidemiology (MOOSE) Group and the PRISMA 2009 guidelines.10, 11 We searched for all 
prospective cohort and other related studies that evaluated the associations between BMI and 
all-cause mortality in patients either with heart failure and a reduced (HFrEF; LVEF <40%) 
or preserved ejection fraction (HFpEF; LVEF ≥ 50%). Only studies with at least three 
categories of BMI were considered.12 Studies13-15 with patients with a mean left ventricular 
ejection fraction (LVEF) close to 45% were not included as the patients could not be reliably 
classified as having predominantly HFpEF or HFrEF. To reduce bias, only prospective cohort 
studies were included, including an individual patient-data meta-analysis.8  
 
PubMed and Embase from June 1980 to April 2017 were searched evaluating associations 
between BMI and all-cause mortality in patients with HFrEF or HFpEF. There were no 
language restrictions. Search terms included: HFpEF, HFrEF, HFnEF, reduced, normal or 
preserved EF, reduced, normal or preserved ejection fraction, BMI, body mass index, 
mortality and death. We also searched reference lists of the retrieved articles to identify other 
eligible studies. Two investigators independently reviewed all titles and abstracts from the 
search results to identify articles that met the inclusion criteria. Selected studies were 
compared, and disagreement was resolved by discussion and consensus. If any of the 
eligibility criteria were not met, the article was excluded. If results were incomplete or 
unclear, attempts were made to contact the study authors. Articles finally selected for review 
were checked to avoid inclusion of data published in duplicate. Relevant information was 
collected on baseline characteristics, such as age, sex, New York Heart Association (NYHA) 
functional classification, HF phenotype, heart rhythm at baseline, mean follow-up and events.  
 
Statistical Analysis 
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The hazard ratio (HR) with 95% confidence intervals for all-cause mortality in each baseline 
BMI category obtained from multivariable models for all studies was used as the effect size. 
A dose-response association between BMI and all-cause mortality was assessed by the 
methods described by Greenland and Longnecker16 and Orsini17 based on a generalized least 
squares regression model using STATA version 14.2. We assumed that the reference 
category was the lowest BMI category for each study. For studies in which the reference 
group was not the lowest category, we transformed it to the lowest category using the method 
proposed by Orsini.18 We used the mid-point of the corresponding range of BMI as the 
exposure value. When upper and lower categories were open-ended, we used the width of the 
adjacent category to calculate an upper or lower bound.  
 
For studies that did not report the number of person-years by BMI category, we used 
approximated values based on follow-up period, number of subjects provided and number of 
BMI categories. One study19 reported results for peak oxygen uptake ≤14 and >14 ml.kg-
1.min-1 separately; we combined the estimated hazard ratios using a fixed effect model to 
obtain an overall estimate. A potential non-linear relationship between BMI and mortality 
was evaluated by modelling BMI dose with the use of restricted cubic splines with 4 knots at 
fixed centiles (5%, 35%, 65% and 95%) based on all categories of BMI for all studies, and 
examined by testing the hypothesis that the regression coefficients of the spline 
transformations were all equal to zero. We produced a dose-response curve with a re-scaled 
reference category of BMI of 23.8 kg/m2, which we took as a value within the normal weight 
range. Summary estimated effect sizes were obtained using a random effects model based on 
each study calculated using the method of Orsini et al.20 Heterogeneity was assessed using Q 
test and I-squared statistics.21 Forest plots were used to represent graphically the results 
generated from the random-effects meta-analysis. The pooled HR and the degree of 
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heterogeneity are presented. Publication-bias was minimized by comprehensive literature 
searching. In addition, Begg’s test22 and Egger’s test23 were used to investigate publication 
bias.  
 
Results 
The selection process and results are shown in Figure 1. Of 622 articles found by the initial 
search, 47 were retrieved for more detailed evaluation. Ten studies were identified with 
96,424 patients, for whom the mean age was 64 years; 28% were women. The biggest study 
contained 47,866 patients24 and the smallest study 446 patients.25 Where NYHA class was 
reported, most patients were in class III or IV. One study included only women26 and one 
study included predominantly (96%) men.3  
 
Most studies were conducted in the United States of America (Table 1). Patients with a 
higher BMI were more likely to have a history of diabetes and hypertension, especially for 
patients with HFpEF. Patients with a BMI in the normal range were more likely to have IHD 
(Table 2). Patients with HFrEF were more likely to take digoxin (Table 3). Of the ten 
studies, nine reported all-cause mortality, three reported cardiovascular (CV) mortality and 
one reported death/urgent heart transplant/or ventricular assist device.19  
 
HFpEF  
Four studies3, 8, 24, 27 including one individual patient data meta-analysis8 included 59,263 
patients of whom 6,061 died. The average patient age was 68 years, and 38% were women. In 
multivariable analysis, the variables most commonly adjusted for were: age, sex, LVEF, 
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diabetes, blood pressure, NYHA class, ischaemic aetiology and hypertension (Table 4). The 
summary HR per 5 unit increment in BMI was 0.93 (95%CI: 0.89-0.97) (I-squared = 75.8%, 
p for heterogeneity=0.01 (Figure 2A)), with an inverse association between BMI and all-
cause mortality. There was no evidence of publication bias (Begg’s test, p=1.0 or Egger’s 
test, p=0.29). The dose-response meta-analysis showed a U-shaped association between BMI 
and all-cause mortality with the lowest mortality at a BMI of 32-33 kg/m2 (p<0.01 for non-
linearity, Figure 3A). Similar results were found when the MAGGIC meta-analysis8 was 
excluded (leaving n = 53,210 patients). There were too few studies to investigate an 
interaction between age and mortality for patients with HFpEF (Table 5). 
 
HFrEF 
Seven studies were identified8, 19, 25, 26, 28-30 with 37,161 patients of whom 12,429 died. The 
average patient age was 60 years and 17% were women. In multivariable analysis, the 
variables most commonly adjusted for were: age, sex, LVEF, diabetes, blood pressure, 
NYHA class, ischaemic aetiology and hypertension (Table 4). The summary HR per 5 unit 
increment in BMI was 0.96 (95%CI: 0.92-0.99) (I-squared = 95%, p for heterogeneity<0.001 
(see Figure 2B)). There was no evidence of publication bias (Begg’s test, p=0.45, Egger’s 
test, p=0.01). The dose-response meta-analysis showed a ‘flatter’ U-shaped association than 
for HFpEF with the lowest mortality at a BMI of 32 kg/m2 (p<0.01) (Figure 3B). Similar 
results were found excluding the MAGGIC meta-analysis8 (leaving n= 21,205 patients). The 
negative relationship was statistically significant for patients with HFrEF who were aged >60 
years (HR: 0.95 (0.92-0.97), p<0.05), but not for patients aged <60 years (HR: 0.97 (0.91-
1.03), p>0.05), and the p-values for heterogeneity were different for each group (see Table 5).  
One study30 showed a negative relation between BMI and CV deaths in patients with HFrEF 
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without giving detailed data. Another study28 provided detailed data, and found a ‘flatter’ U-
sharped relation between BMI and CV deaths than between BMI and all-cause mortality 
amongst patients with HFrEF (Table 2).  
 
Discussion 
This analysis confirms, in part, the existence of an obesity-paradox for patients with heart 
failure. However, rather than a linear relationship between greater BMI and longevity, we 
observed, as anticipated, a U-shaped relationship; very low body weight and extreme obesity 
are both known to be dangerous. Previous studies have reported a U-shaped relationship 
between BMI and mortality with a nadir anywhere between 30 kg/m2 26 and 42 kg/m2.31 Our 
analysis provides a considerably narrower range for the nadir of risk both for HFpEF and 
HFrEF at a BMI of 32-33 kg/m2 although the U-shaped relationship was ‘flatter’ for HFrEF.  
 
There are many possible explanations for the ‘obesity-paradox’ in patients with heart failure. 
Obesity may be a risk factor for developing heart failure at an earlier age; younger patients 
generally have a better prognosis.32-35 Thus, so called “reverse-causation” could account for 
the relationship between obesity and prognosis. Obesity might induce symptoms, such as 
breathlessness on exertion or lying down, leading to earlier diagnosis of heart failure or even 
misdiagnosis. Obesity might indicate less advanced disease. Weight loss is an ominous sign 
in patients with heart failure even before patients become notably cachectic.35-37 A recent 
report38 suggested that patients with heart failure and a greater waist-hip ratio had a worse 
prognosis. This may reflect the pro-inflammatory response to accumulation of 
visceral/omental fat. Obesity is also associated with the development of type 2 diabetes that is 
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associated with an adverse prognosis in patients with heart failure. The proportion of patients 
with diabetes increases with BMI regardless of HF phenotype in all studies. 
 
Alternatively, obesity might be protective. Fat might provide an energy reserve that helps a 
patient cope with the metabolic costs of illness, protecting muscle and bone from the 
catabolic effects of worsening heart failure. Fat might also provide protection against 
endotoxins.39,40,41,42,8, 43,44,45 Treatment with beta-blockers causes BMI to rise and improves 
the prognosis of patients with HFrEF, although it is unclear whether this relationship is 
causal. However, ESC guidelines on heart failure no longer advise weight loss in moderately 
obese in patients.46 
 
Many reports suggest an obesity-paradox for patients aged >50 years with established cardio-
metabolic disease. This is true for hypertension47, type-2 diabetes mellitus48, 49, atrial 
fibrillation50, 51 and ischaemic heart disease52 as well as heart failure53-55. Reverse-causation 
could explain each instance. On the other hand, from a clinical perspective it is the prognosis 
of the patient who they are caring for that is important rather than the patient’s prior medical 
history, which cannot be altered. Accordingly, knowing that a patient with heart failure who 
is slightly obese has a better prognosis might be helpful for making decisions about 
management. Patients might be advised to lose weight (and take more exercise) to improve 
symptoms and exercise capacity but whether this will have a beneficial or deleterious effect 
on longevity is unknown. 
 
This is the first study using a dose-response meta-analysis to evaluate the association between 
BMI and all-cause mortality in patients with HFrEF and HFpEF. The advantage of using the 
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method is that it provides estimates that better quantify the potential non-linear relation 
between BMI and all-cause mortality. Another advantage of the approach is that it does not 
require the use of the same cut points for BMI in all studies, which means that all the BMI 
data can be used.  
 
One problem in interpreting the data is the definition of HFpEF. Many people have 
“abnormal” features of diastolic function in association with increasing age and obesity. In 
the absence of conclusive evidence of cardiac dysfunction (such as atrial dilatation or raised 
plasma concentrations of natriuretic peptides), the diagnosis of heart failure is in doubt. 
Amongst the studies of HFpEF that we have included, only one (Haass et al.27) reported 
plasma concentrations of natriuretic peptides which, although raised, were much lower than 
typically seen in clinical trials of patients with HFrEF.  
 
The study has several other limitations. Some patients with an LVEF of 40-49% (HFmrEF) 
will have been misclassified as either HFrEF or HFpEF. We did not include studies where the 
mean value for LVEF was around 45%13, 15, 56 because it was not clear what proportion of 
these patients would have HFrEF or HFpEF. The characteristics and treatment of patients 
varied across cohorts as might be expected and differed in adjusted variables and follow-up 
time. We used a random effect model and most studies were controlled for age, sex, left 
ventricular ejection fraction, diabetes, blood pressure, NYHA class, ischemic aetiology and 
hypertension. We only included studies with BMI given in more than 2 categories, which 
potentially limits the number of studies. However, it makes more efficient for dose-response 
meta-analysis. In addition, weight changes in patients with heart failure, but the data are not 
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available from the studies included in our meta-analysis to investigate the relation between 
weight change and outcome. 
  
The relation between BMI and outcome might depend on the end-point chosen. Patients with 
HFpEF are more likely to die from non-cardiovascular causes than are patients with HFrEF57 
but cause-specific mortality data were not available. Furthermore, no data are available to 
allow us to explore the effect of inflammation or dysglycaemia on the relation between BMI 
and survival.  
 
Conclusion 
Both for patients with HFpEF and HFrEF, the relationships between BMI and mortality are 
U-shaped with a similar nadir of risk at a BMI of 32-33 kg/m2. Whether interventions to 
change BMI alter risk is unknown. Further research is required to discover the reasons 
underlying the obesity-paradox in heart failure and other cardio-metabolic diseases and to 
provide guidance on whether and how patients should attempt to lose or gain weight.   
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Figure legend 
Figure 1: Flowchart of search process. 
Figure 2: Adjusted relative risk (HR) for all-cause mortality per 5 units increment in BMI. 
(A): HFpEF; B): HFrEF). HR and 95% CI are represented by the black dot and horizontal 
line, respectively; the area of the grey square is proportional to the specific-study weight to 
the overall meta-analysis. 
Figure 3: Association between BMI and all-cause mortality. A reference is set at BMI=23.8 
(the top (A): HFpEF; the bottom (B): HFrEF). The middle boxes show the range of BMI for 
which the relative risk is <1.0 compared to the reference BMI.    
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Figure 2: Adjusted relative risk (HR) for all-cause mortality per 5 units increment in BMI. 
(A): HFpEF; B): HFrEF). HR and 95% CI are represented by the black dot and horizontal 
line, respectively; the area of the grey square is proportional to the specific-study weight to 
the overall meta-analysis. 
NOTE: Weights are from random effects analysis
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Table 1: Baseline characteristics for included studies  
Study Pub 
Year 
Number of 
patients 
Source Follow-up 
(years) 
HF phenotype Age (years) 
Mean (SD) 
Women 
(%) 
NYHA class  
(%) 
Haass 2011 4,109 USA 4.1 HFpEF  
 
72 60.4 II/III/IV: 
3/9/0 
DeShutter  2014 47,866 USA 3.1  HFpEF 61.6 (15.4) 55 - 
Kapoor  2010 1,236 USA 1.0 HFpEF 71 (12) 4 - 
Padwal 2014# 22,009 MAGGIC 3.0 HFrEF:15,956 patients 
HFpEF: 6,053 patients 
66.8 32 II/III: 46/50 
Vest 2015 3,811 USA 6.0 HFrEF 
 
54.1 (11.6) 100 I/II/III/IV: 
8/31/59/2 
Curtis  2005 7,767 USA & 
Canada 
3.1 HFrEF 
 
64 (11) 24.6 I/II/(III or IV): 
14.3/54.5/31.3 
Zafrir 2015 630 Israel 3.3 HFrEF 65 (13) 20 III or IV: 53 
Clark  2015 1,675 USA 2.0 HFrEF 52.2 (11.6) 22.6 III or V: 79.1 
Wu 2009 446 USA 0.8 HFrEF 62.2 27.6 - 
McAuley  2007 6,876 USA 7.5  HFrEF  58 (11) 10 - 
NYHA class: New York Heart Association functional classification; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure 
with reduced ejection fraction. # the MAGGIC meta-analysis was based on studies originally reported between 1992 and 2006; data collection 
will have occurred several years earlier [9].   
 
 
 
Table 2: Patients comorbidities and mortalities 
Study HF 
phenotype 
BMI group IHD  
(%) 
Diabetes  
(%) 
COPD  
(%) 
Hypertension 
(%) 
Blood pressure 
(mean) 
(Systolic/diastolic) 
Creatinine(mg/ 
dL)/ eGFR  
(mean with SD) 
All-cause / 
CV mortality 
 N (%) 
Reported 
natriuretic 
peptide 
level  
Haass 2011 HFpEF  
 
<23.5 
23.5-26.4 
26.5-30.9 
31.0-34.9 
>35.0 
- 18 
20 
27 
31 
41 
10 
10 
8 
9 
13 
76 
87 
88 
92 
92 
134/77 
135/78 
136/71 
138/72 
137/73 
1 (0.3)/68(23) 
1(0.3)/73 (23) 
1 (0.3)/73 (22) 
1(0.4)/72 (23) 
1(0.3)/71 (24)  
108(32%)/68(20%) 
205(24)/124(15) 
287(19)/168(11) 
151(19)/93(12) 
123(21)/74(12) 
(did not report HR) 
Yes 
DeShutter 2014 HFpEF  <=30 
>30 
- - - - 135/73 
138/77 
- Did not report CV 
deaths 
No 
Kapoor 2010 HFpEF <20 
20-25 
26-30 
31-35 
36-40 
41-45 
>45 
59 
61 
57 
64 
61 
57 
37 
33 
35 
37 
57 
66 
72 
59 
- 82 
86 
82 
89 
90 
95 
87 
Any diastolic 
dysfunction (%): 
67,93,86, 
80 
85 
70 
92 
Creatinine>1.5 
(%): 41 
34 
37 
40 
36 
51 
37 
Did not report CV 
deaths 
No 
Padwal 2014 HFpEF <22.5 
22.5-24.9 
25-29.9 
30-34.9 
>=35 
40 
45 
48 
44 
35 
11 
15 
19 
28 
36 
- 32 
41 
48 
61 
68 
135/75 
137/77 
139/80 
140/80 
142/81 
- Did not report CV 
deaths 
No 
HFrEF <22.5 
22.5-24.9 
25-29.9 
30-34.9 
>=35 
52 
57 
59 
56 
47 
13 
17 
22 
31 
39 
- 25 
31 
37 
49 
59 
124/74 
126/76 
129/77 
132/79 
133/80 
- Did not report CV 
deaths 
No 
Vest 2015 HFrEF 18.5-24.99 
25-29.99 
>=30 
46 
51 
44 
17 
26 
38 
- 44 
54 
66 
SBP (media): 104 
110 
110 
- Did not report CV 
deaths 
No 
Curtis 2005 HFrEF 
 
<18.5 
18.5-24.9 
25-29.9 
>=30 
61 
68 
74 
63 
18 
20 
29 
41 
- 40 
40 
46 
59 
SBP (mean): 124 
124 
127 
132 
1.2 
1.3 
1.3 
1.2 
72(45)/45(28) 
977(38)/840(33) 
998(32)/833(27) 
550(28)/473(24) 
(reported HR) 
No 
Zafrir 2015 HFrEF <25.5 
25.5-30.4 
>30.4 
- 34 
45 
55 
- 49 
59 
70 
- 1.40 
1.38 
1.33 
Did not report CV 
deaths 
No 
Clark 2015 HFrEF 18.5-24.9 
25-29.9 
>=30 
- 19 
28 
33 
- 32 
44 
47 
- - Did not report CV 
deaths 
No 
Wu 2009 HFrEF 18.5-24.9 
25-24.9 
>=30 
- 20 
25 
37 
- 55 
59 
65 
135/79 
134/80 
136/80 
Initial/peak 
creatinine: 
1.40/1.45 
1.21/1.51 
1.32/1.24 
Did not report CV 
deaths 
No 
McAuley 2007 HFrEF  18.5-24.9 
25-29.9 
>=30 
- 7 
11 
16 
- 38 
47 
59 
130/79 
133/82 
135/84 
- Reported a 
negative relation 
between BMI and 
CV deaths 
No 
IHD: Ischaemic heart disease, HFpEF: heart failure with preserved ejection fraction, HFrEF: heart failure with reduced ejection fraction, HR: 
hazard ratio. 
 
 
 
Table 3: Baseline medications 
Study HF 
phenotype 
BMI 
group 
Diuretic  
(%) 
Spirono-
lactone 
(%) 
ACE 
inhibitor / 
ARB (%) 
Beta-
blocker 
(%) 
Digoxin 
 (%) 
Calcium 
channel 
blocker (%) 
Lipid-
lowering 
agent (%) 
Anti-
platelet 
agent (%) 
Statins 
(%) 
Nitrates 
(%) 
Haass 2011 HFpEF  
 
<23.5 
23.5-26.4 
26.5-30.9 
31.0-34.9 
>35.0 
78 
81 
82 
83 
91 
20 
14 
15 
14 
17 
23 
23 
25 
28 
28 
50 
59 
59 
61 
63 
20 
15 
13 
14 
10 
31 
36 
39 
45 
46 
25 
27 
33 
29 
35 
52 
63 
61 
58 
53 
-  
DeShutter 2014 HFpEF  <=30 
>30 
- - - - - - - - -  
Kapoor 2010 HFpEF <20 
20-25 
26-30 
31-35 
36-40 
41-45 
>45 
46 
49 
52 
56 
59 
78 
69 
- 38 
52 
53 
57 
52 
76 
59 
46 
45 
45 
54 
53 
59 
50 
17 
21 
17 
15 
8 
7 
7.4 
29 
40 
37 
42 
37 
41 
37 
- - 27 
43 
47 
58 
56 
54 
43 
 
Padwal 2014 HFpEF <22.5 
22.5-24.9 
25-29.9 
30-34.9 
>=35 
76 
76 
74 
81 
86 
18 
17 
16 
15 
20 
32 
35 
36 
42 
36 
25 
34 
40 
43 
42 
42 
35 
32 
28 
25 
- - - -  
HFrEF <22.5 
22.5-24.9 
25-29.9 
30-34.9 
>=35 
86 
83 
83 
84 
89 
28 
25 
23 
25 
25 
68 
72 
70 
68 
65 
30 
38 
42 
48 
49 
59 
53 
49 
46 
46 
- - - -  
Vest 2015 HFrEF 18.5-24.99 
25-29.99 
>=30 
- - 91 
92 
92 
63 
69 
73 
69 
62 
61 
- - - -  
Curtis 2005 HFrEF 
 
<18.5 
18.5-24.9 
25-29.9 
94 
85 
84 
- 96 
93 
93 
- 42 
41 
43 
- - - - 42 
41 
43 
>=30 89 94 44 44 
Zafrir 2015 HFrEF <25.5 
25.5-30.4 
>30.4 
- - 85 
89 
89 
90 
96 
94 
- - - - - - 
Clark 2015 HFrEF 18.5-24.9 
25-29.9 
>=30 
31 
41 
46 
- - 56 
64 
71 
- - - - - - 
Wu 2009 HFrEF 18.5-24.9 
25-24.9 
>=30 
38 
41 
40 
- 73 
76 
72 
73 
84 
81 
18 
17 
8 
8 
6 
10 
- - 65 
70 
73 
- 
McAuley 2007 HFrEF  18.5-24.9 
25-29.9 
>=30 
- - - 15 
20 
23 
- 22 
23 
26 
- Antihypert
ensive 
agent 
16 
20 
23 
- - 
IHD: Ischaemic heart disease, HFpEF: heart failure with preserved ejection fraction, HFrEF: heart failure with reduced ejection fraction. ‘ –‘ did 
not report. 
 
Table 4: Hazard and Odds Ratios for All-cause Mortality by BMI Category for the included studies 
 HFpEF HFrEF 
Study BMI 
Category  
HR/OR 
(95% CI) 
Adjusted covariates BMI 
Category 
 
HR/OR  
(95% CI) 
Adjusted covariates 
Haass 2011 <23.5 
23.5-26.4 
26.5-30.9 
31.0-34.9 
>35.0 
1.44 (1.12-1.84) 
1.18 (0.9 - 1.4) 
1 (1 – 1) 
1.07 (0.90-1.41) 
1.31 (1.03-1.67) 
Age, sex, NYHA class, heart rate, systolic 
blood pressure, left ventricular hypertrophy, 
LVEF, cause of HF, hospitalization for HF 
within the last 6 months, hypertension, 
myocardial infarction, stroke, COPD and/or 
diabetes, use of diuretics, digoxin, a calcium-
channel blocker, lipid-lowering agents, an 
ACE-inhibitor, or a beta-blocker, and NT-
proBNP. 
- - - 
DeShutter 
2014 
<18.5 
18.5-20 
20-25 
25-30 
30-35 
35-40 
>40 
1.9 (1.6-2.3) 
1.5 (1.3 -1.7) 
1 (1 - 1) 
0.8 (0.7 - 0.9) 
0.7 (0.6 - 0.8) 
0.8 (0.8 - 1.1) 
1.2 (0.9 -1.3) 
Left ventricular mass index, age, sex, 
ejection fraction, and relative wall 
thickness. 
- - - 
Padwal 2014 <22.5 
22.5-24.9 
25-29.9 
30-34.9 
>=35 
1.12 (0.8 -1.57) 
1 (1 -1) 
0.74 (0.56 -0.97) 
0.64 (0.46 -0.88) 
0.71 (0.49 -1.05) 
Age, sex, aetiology (ischaemic or non-
ischaemic), hypertension, diabetes and 
baseline blood pressure 
<22.5 
22.5-24.9 
25-29.9 
30-34.9 
>=35 
1.31 (1.15 -1.5) 
1 (1 – 1) 
0.85 (0.76 -0.96) 
0.64 (0.55 -0.74) 
0.95 (0.78 -1.15) 
Age, sex, aetiology (ischaemic or non-
ischaemic), hypertension, diabetes and 
baseline blood pressure 
Vest 2015 - - - 18.5-24.99 
25-29.99 
>=30 
1 (1 -1) 
1.08 (1.03 -1.13) 
1.09 (1.04 -1.14) 
Age, race, ischemic etiology, NYHA, digoxin, 
ACE inhibitor/ARB, beta-blocker, diabetes, 
smoking, HTN, hypercholesterolemia, AF, 
resting SBP, HRR, peak VO2, peak RER, peak 
Vt, subsequent transplant or LVAD. 
Kapoor 2010 <20 
20-25 
26-30 
1.68 (1.04 -2.65) 
1.25 (0.92 -1.68) 
1 (1 -1) 
Age, history, medications, and 
laboratory and echocardiographic 
variables. 
- - - 
31-35 
36-40 
41-45 
>45 
0.99 (0.71 -1.36) 
0.58 (0.35 -0.97) 
0.79 (0.44 -1.4) 
1.38 (0.74 -2.6) 
Curtis 2005 - - - <18.5 
18.5-24.9 
25-29.9 
>=30 
1.21 (0.95 -1.53) 
1 (1 -1) 
0.88 (0.8 -0.96) 
0.81 (0.72 -0.92) 
Age; sex; LVEF; New York Heart 
Association class; history of 
myocardial infarction; dyspnea; 
duration of HF symptoms; diabetes; 
hypertension; HF etiology; blood 
pressure; heart rate; rales; elevated 
jugular venous pressure; peripheral 
oedema.  
McAuley 2007 - - - 18.5-24.9 
25-29.9 
>=30 
1 (1-1) 
0.70 (0.63-0.79) 
0.65 (0.57-0.76) 
Age, sex, CVD, smoking, 
hypertension, hypercholesterolemia, 
myocardial infarction, stroke or 
surgery for CVD and metabolic 
equivalent. 
Zafrir 2015 - - - <25.5 
25.5-30.4 
>30.4 
1.11 (0.79-1.55) 
1.02 (0.73-1.44) 
1 (1-1) 
Sex, hypertension, history of 
myocardial infarction, left ventricular 
ejection fraction, 
permanent/paroxysmal atrial 
fibrillation,left atrial dimension, QRS 
width, haemoglobin and creatinine 
level, NYHA grade and 
beta-blockers. 
Clark 2015 
 
 
- - - 18.5-24.9 
25-29.9 
>=30 
Peak oxygen 
uptake<=14: 
1 (1-1) 
0.91(0.66-1.25) 
0.64 (0.44-0.91); 
Peak oxygen 
uptake>14: 
1 (1-1) 
0.75(0.43-1.32) 
Age, diabetes, left ventricular 
ejection fraction, ACE inhibitor/ARB 
use, New York Heart Association 
class, and heart failure etiology 
(ischemic vs non-ischemic). 
0.87(0.43-1.75) 
 
Wu, 2009 - - - 18.5-24.9 
25-24.9 
>=30 
1 (1-1) 
0.63 (0.42-0.94) 
1.06 (0.69-1.64) 
Sex, age, diabetes, LVEF, blocker 
prescribed at hospital discharge, 
angiotensin-converting enzyme 
inhibitor or angiotensin receptor 
blocker prescribed at discharge, 
initial creatinine, and hemoglobin. 
HFpEF: heart failure with preserved ejection fraction, HFrEF: heart failure with reduced ejection fraction.  
 
Table 5: The associations between BMI and all-cause mortality by different age groups  
 HFrEF HFpEF 
Age 
groups 
N HR 
(95% CI) 
I2 (%) P-heterogeneity 
(in the group of 
studies) 
N HR 
(95% CI) 
I2 (%) P-heterogeneity 
(in the group of 
studies) 
≥60 4 0.95 (0.92-0.97) 
(p<0.05) 
42% 0.16 4 0.93 (0.89-0.97) 
(p<0.05) 
76% 0.006 
<60 3 0.97 (0.91-1.03) 
(p>0.05) 
97% <0.001 0 - - - 
 
≥65 2 0.95 (0.91-1.00) 
(p>0.05) 
69 % 0.07 3 0.95 (0.92-0.97) 
(p<0.05) 
0% 0.57 
<65 5 0.96 (0.92-1.01) 
(p>0.05) 
95% <0.001 1 0.89 (0.87-0.91) 
(p<0.05) 
- - 
 
 
